Predicting sales of new medicines is highly inaccurate and subject to significant and often costly errors. While investment analysts can draw on research tools and experience, history suggests new drug forecasting will remain more art than science. Despite the high level of uncertainty and variability in new drug forecasts, the innovative medicine industry is alive
Harlan Sonderling, CFA, Senior Healthcare Analyst
Harlan Sonderling is a senior equity analyst for fundamental research covering stocks in the healthcare sector at Columbia Management Investment Advisers, LLC (CMIA). Mr. Sonderling joined the firm in 2001 and has been a member of the investment community since 1986.
Prior to joining the firm, Mr. Sonderling was a vice president, research analyst and portfolio manager for Evergreen Investment Management. Previously, he was a vice president, research analyst and portfolio manager at Putnam Investments; vice president and equity research director at Mutual of America Life Insurance; vice president and portfolio manager at Dalton, Greiner, Hartman, Maher & Company and an equity research analyst at Sanford C. Bernstein. Mr. Sonderling began his career as an auditor and tax consultant for Arthur Andersen.
Mr. Sonderling earned a B.A. from Brown University and an M.B.A. from the Stern School of Business at New York University. He is a member of the CFA Institute and the Boston Security Analysts Society. In addition, he holds the Chartered Financial Analyst and Certified Public Accountant designations.